Teruki Miyake1, Masashi Hirooka1, Osamu Yoshida1, Shinya Furukawa2, Teru Kumagi1,3, Mitsuhito Koizumi1,4, Shin Yamamoto1, Taira Kuroda1, Eiji Arimitsu1, Eiji Takeshita1, Masanori Abe1, Kohichiro Kitai4, Bunzo Matsuura1, Yoichi Hiasa5. 1. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. 2. Department of Public Health, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan. 3. Department of Community Medicine, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan. 4. Ehime General Health Care Association, Misake, Matsuyama, Ehime, Japan. 5. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. hiasa@m.ehime-u.ac.jp.
Abstract
BACKGROUND: It remains unclear whether fatty liver is a risk factor for the onset of abnormal glucose tolerance in any patient. The objective of this study was to clarify the relationship between fatty liver and the onset of impaired fasting glucose according to baseline fasting plasma glucose (FPG) levels. METHODS: This community-based longitudinal cohort study included 7,905 adults (3,863 men, 4,042 women; age range, 18-80 years) who had at least two annual checkups between 2003 and 2013. Those with FPG levels ≥110 mg/dl, taking anti-diabetic agents, and/or testing positive for hepatitis B surface antigen or anti-hepatitis C virus antibody were excluded, leaving 7,203 participants eligible for inclusion. All participants were divided into quartiles derived from their FPG levels at baseline. FPG ≥110 mg/dl during the observation period was defined as onset of IFG. RESULTS: Onset of IFG was found in 7.7 % of men and 2.1 % of women (p < 0.001). After adjusting for age, body mass index, systolic blood pressure, triacylglycerol, high-density lipoprotein cholesterol, uric acid, creatinine, family history of diabetes, alcohol consumption, and current smoking, a positive association was found between fatty liver and the onset of IFG in both sexes with the highest quartile of FPG levels [men: adjusted hazard ratio (aHR) 1.823, 95 % confidence interval (CI) 1.316-2.534, p < 0.001; women: aHR 2.016, 95 % CI 1.117-3.6, p = 0.02]. CONCLUSIONS: Our results suggest that fatty liver is independently associated with an increased risk of developing IFG in individuals with high FPG.
BACKGROUND: It remains unclear whether fatty liver is a risk factor for the onset of abnormal glucose tolerance in any patient. The objective of this study was to clarify the relationship between fatty liver and the onset of impaired fasting glucose according to baseline fasting plasma glucose (FPG) levels. METHODS: This community-based longitudinal cohort study included 7,905 adults (3,863 men, 4,042 women; age range, 18-80 years) who had at least two annual checkups between 2003 and 2013. Those with FPG levels ≥110 mg/dl, taking anti-diabetic agents, and/or testing positive for hepatitis B surface antigen or anti-hepatitis C virus antibody were excluded, leaving 7,203 participants eligible for inclusion. All participants were divided into quartiles derived from their FPG levels at baseline. FPG ≥110 mg/dl during the observation period was defined as onset of IFG. RESULTS: Onset of IFG was found in 7.7 % of men and 2.1 % of women (p < 0.001). After adjusting for age, body mass index, systolic blood pressure, triacylglycerol, high-density lipoprotein cholesterol, uric acid, creatinine, family history of diabetes, alcohol consumption, and current smoking, a positive association was found between fatty liver and the onset of IFG in both sexes with the highest quartile of FPG levels [men: adjusted hazard ratio (aHR) 1.823, 95 % confidence interval (CI) 1.316-2.534, p < 0.001; women: aHR 2.016, 95 % CI 1.117-3.6, p = 0.02]. CONCLUSIONS: Our results suggest that fatty liver is independently associated with an increased risk of developing IFG in individuals with high FPG.
Authors: K Waki; M Noda; S Sasaki; Y Matsumura; Y Takahashi; A Isogawa; Y Ohashi; T Kadowaki; S Tsugane Journal: Diabet Med Date: 2005-03 Impact factor: 4.359
Authors: Barbora Vozarova; Norbert Stefan; Robert S Lindsay; Aramesh Saremi; Richard E Pratley; Clifton Bogardus; P Antonio Tataranni Journal: Diabetes Date: 2002-06 Impact factor: 9.461
Authors: Earl S Ford; Matthias B Schulze; Manuela M Bergmann; Claus Thamer; Hans-Georg Joost; Heiner Boeing Journal: Diabetes Care Date: 2008-03-17 Impact factor: 19.112
Authors: Stefan Kabisch; Nina M T Meyer; Caroline Honsek; Christiana Gerbracht; Ulrike Dambeck; Margrit Kemper; Martin A Osterhoff; Andreas L Birkenfeld; Ayman M Arafat; Mads F Hjorth; Martin O Weickert; Andreas F H Pfeiffer Journal: Nutrients Date: 2019-10-06 Impact factor: 5.717
Authors: Stefan Kabisch; Nina Marie Tosca Meyer; Caroline Honsek; Christiana Gerbracht; Ulrike Dambeck; Margrit Kemper; Martin A Osterhoff; Andreas L Birkenfeld; Ayman M Arafat; Martin O Weickert; Andreas F H Pfeiffer Journal: Nutrients Date: 2019-11-11 Impact factor: 5.717